Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 9/20 | 0.64 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.52 |
| ▸ | CCR5 | P51681 | 1/20 | 0.50 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318723 | 0.93 | NPC1L1 (0.59) | NPC1L1BDKRB2OPRD1OPRK1OPRM1 | |
| SCHEMBL8811610 | 0.93 | NPC1L1 (0.57) | NPC1L1OPRD1OPRK1 | |
| SCHEMBL10248111 | 0.92 | NPC1L1 (0.63) | NPC1L1BDKRB2 | |
| SCHEMBL318225 | 0.91 | NPC1L1 (0.59) | NPC1L1BDKRB2CCR5DDR1 | |
| SCHEMBL318756 | 0.91 | NPC1L1 (0.61) | NPC1L1DDR1 | |
| SCHEMBL318333 | 0.90 | NPC1L1 (0.56) | NPC1L1BDKRB2CCR5DDR1 | |
| SCHEMBL10248363 | 0.90 | NPC1L1 (0.58) | NPC1L1BDKRB2DDR1 | |
| SCHEMBL12490745 | 0.89 | NPC1L1 (0.59) | NPC1L1BDKRB2DDR1 | |
| SCHEMBL1855447 | 0.88 | NPC1L1 (0.70) | NPC1L1BDKRB2OPRK1OPRM1DDR1 | |
| SCHEMBL319932 | 0.88 | NPC1L1 (0.55) | NPC1L1DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678177-B1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-11-28 | — | — | EP | disclosed |
| US-7189850-B2 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189850-B2 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189850-B2 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1678177-A1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-12 | — | — | EP | disclosed |
| EP-1256575-B1 | PHENOXYALKYLAMINE DERIVATIVES USEFUL AS OPIOID DELTA RECEPTOR AGONISTS | MEIJI SEIKA KAISHA (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-6916822-B2 | Phenoxyalkylamine derivatives useful as opioid δ receptor agonists | MEIJI SEIKA KAISHA, LTD. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20050148583-A1 | Phenoxyalkylamine derivatives useful as opioid delta receptor ligands | MEIJI SEIKA KAISHA, LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| US-20050107373-A1 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-19 | — | — | US | disclosed |
| WO-2005040166-A1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-20030171370-A1 | Phenoxyalkylamine derivatives useful as opioid receptor agonists | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| EP-1256575-A1 | PHENOXYALKYLAMINE DERIVATIVES USEFUL AS OPIOID DELTA RECEPTOR AGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171370-A1 | Phenoxyalkylamine derivatives useful as opioid receptor agonists | OPRM1, OPRK1, OPRD1 | NPC1L1 2499/4885BDKRB2 109/4885OPRD1 3/4885 |
| US-20050148583-A1 | Phenoxyalkylamine derivatives useful as opioid delta receptor ligands | OPRD1, OPRM1, OPRK1 | NPC1L1 2327/4885BDKRB2 126/4885OPRD1 1/4885 |
| US-20050107373-A1 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | GRIN1, GRIN2A, GRM1 | NPC1L1 3343/4885BDKRB2 1829/4885OPRD1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.